This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Abiomed Announces Publication Of Protect II Cost Effectiveness Study In American Health & Drug Benefits Journal

Stocks in this article: ABMD

DANVERS, Mass., May 1, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced the publication of the PROTECT II Cost Effectiveness Study in the American Health & Drug Benefits (AHDB) journal, titled "A Value-Based Analysis of Hemodynamic Support Strategies for High-Risk Heart Failure Patients Undergoing a Percutaneous Coronary Intervention."

The study demonstrated a gain in quality of life for Impella patients over the current standard of care, the intra-aortic balloon pump (IABP), at an incremental cost-effectiveness ratio (ICER) of $39,389/QALY (Quality Adjusted Life Year), well below the $100,000/QALY threshold commonly used in the United States or the $50,000/QALY threshold of dialysis.

PROTECT II was the first multicenter, randomized trial comparing non-emergent use of hemodynamic support in patients with depressed left ventricular function and complex anatomy that analyzed both the clinical and economic benefits of hemodynamic support. The clinical trial outcomes data and actual billing data from patients were modeled over ten years using a Markov Model to derive the ICER/QALY.

"This study indicates that new, minimally invasive technologies like Impella provide the opportunity for increased quality care and shared savings opportunities for all stakeholders. As the heart failure population proliferates, decision-makers will need to understand and balance the short-term costs of procedures versus the long-term costs for ongoing care," said David Gregory, MPA, FACHE, author of the study and Executive Vice President and Partner, Presscott Associates - A Division of ParenteBeard, LLC.

"We are very excited about the continued expansion of compelling cost-effectiveness data for the Impella platform, which helps providers and payers navigate the evolving landscape of health care reform," said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed.

The American Health & Drug Benefits ( AHDB) is an independent, peer-reviewed journal founded in 2008 on the concept that health and drug benefits have undergone a transformation: the econometric value of a therapy is currently of equal importance to clinical outcomes as it is to serving as the basis for coverage decisions and benefit designs.

The publication of this PROTECT II Cost Effectiveness study is one of several published or presented data sets from 2012-2013 that all demonstrate the cost effectiveness of Impella.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,678.70 +6.10 0.03%
S&P 500 2,057.09 +5.27 0.26%
NASDAQ 4,771.7630 +13.8840 0.29%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs